ReviewFrontiers in pharmacology2025
Global research trends and hotspots in aspirin studies (2014-2024): a bibliometric perspective.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aspirin, as one of the most important drugs in medical history, has been continuously explored for over 3,000 years. This study employs bibliometric analysis to examine the research hotspots and trends on aspirin over the past decade. Methods and results: This study retrieved articles and reviews on aspirin from the Web of Science database, covering the period from 2014 to 2024. R software and CiteSpace were employed for visual analysis, revealing trends in publication volume, collaborations, core journals, and keywords distributions. In the past decade, a total of 19,504 papers authored by 88,600 researchers were published, citing 460,704 references. The U.S., China, and Italy lead in publications, with Canada and Australia showing strong collaboration. The authors with the highest contributions include BHATT DL, STEG PG, and WANG YJ. Research hotspots and trends include the following three points: the development of expert recommendations for the use of aspirin in primary cardiovascular prevention into personalized and shared decision-making between doctors and patients; the ongoing need for more evidence regarding the effects of aspirin on different tumors; and the sustained focus on aspirin-related respiratory diseases in future research. Conclusion: Aspirin, a classic drug, continues to have a substantial number of publications, underscoring its lasting impact. The United States, China, and Italy play a leading role in this field. However, there is still a long way to go, and research that is more targeted and beneficial for different refined populations may be a future trend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.